Report overview
Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1), also known as endothelial differentiation gene 1 (EDG1) is a protein that in humans is encoded by the S1PR1 gene. S1PR1 is a G-protein-coupled receptor which binds the bioactive signaling molecule sphingosine 1-phosphate (S1P). S1PR1 belongs to a sphingosine-1-phosphate receptor subfamily comprising five members (S1PR1-5). S1PR1 was originally identified as an abundant transcript in endothelial cells and it has an important role in regulating endothelial cell cytoskeletal structure, migration, capillary-like network formation and vascular maturation. In addition, S1PR1 signaling is important in the regulation of lymphocyte maturation, migration and trafficking.
This report aims to provide a comprehensive presentation of the global market for Sphingosine-1-Receptor Modulators Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sphingosine-1-Receptor Modulators Drugs. This report contains market size and forecasts of Sphingosine-1-Receptor Modulators Drugs in global, including the following market information:
Global Sphingosine-1-Receptor Modulators Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Sphingosine-1-Receptor Modulators Drugs Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Sphingosine-1-Receptor Modulators Drugs companies in 2022 (%)
The global Sphingosine-1-Receptor Modulators Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Fingolimod Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Sphingosine-1-Receptor Modulators Drugs include Novartis, Bristol-Myers Squibb, Johnson & Johnson, Arena Pharmaceuticals, Idorsia, Sun Pharma, Biocon and HEC Pharm Co. Limited, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Sphingosine-1-Receptor Modulators Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Sphingosine-1-Receptor Modulators Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Sphingosine-1-Receptor Modulators Drugs Market Segment Percentages, by Type, 2022 (%)
Fingolimod
Siponimod
Ozanimod
Other
Global Sphingosine-1-Receptor Modulators Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Sphingosine-1-Receptor Modulators Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Other
Global Sphingosine-1-Receptor Modulators Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Sphingosine-1-Receptor Modulators Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Sphingosine-1-Receptor Modulators Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Sphingosine-1-Receptor Modulators Drugs revenues share in global market, 2022 (%)
Key companies Sphingosine-1-Receptor Modulators Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Sphingosine-1-Receptor Modulators Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Arena Pharmaceuticals
Idorsia
Sun Pharma
Biocon
HEC Pharm Co. Limited
Outline of Major Chapters:
Chapter 1: Introduces the definition of Sphingosine-1-Receptor Modulators Drugs, market overview.
Chapter 2: Global Sphingosine-1-Receptor Modulators Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Sphingosine-1-Receptor Modulators Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Sphingosine-1-Receptor Modulators Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Sphingosine-1-Receptor Modulators Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
